Evusheld Monoclonal Antibody Request

Recent Updates:
- Updated Tier 1 and Tier 2 criteria to be more inclusive of high-risk patients (broadened definition of B & T cell depleting therapies and extended period of exposure to these agents for Tier 1 patients to within the past 12 months).
- Updated Tier 1 and Tier 2 criteria to be more inclusive of high-risk patients (broadened definition of B & T cell depleting therapies and extended period of exposure to these agents for Tier 1 patients to within the past 12 months).
- Added Evusheld overview and shared decision making information with a link to the FDA fact sheet.
- Added Evusheld overview and shared decision making information with a link to the FDA fact sheet.
- Added Evusheld overview and shared decision making information with a link to the FDA fact sheet.
- Added Evusheld overview and shared decision making information with a link to the FDA fact sheet.
- Added Evusheld overview and shared decision making information with a link to the FDA fact sheet.

Resources and Updates

- FDA Evusheld healthcare provider fact sheet
- Local Evusheld COVID-19 response resource
- For clinical questions regarding the use of COVID-19 PoPs or COVID patients, contact the COVID-19 Response Resource (4/1/20)
- Evusheld Patient (Phase II & Cardiac Arm A)
- Evusheld Patient (Phase II & Cardiac Arm A)
- Evusheld Patient (Phase II & Cardiac Arm A)

Evusheld (tixagevimab/cilgavimab) Overview
- Evusheld is administered as 2 consecutive infusions of tixagevimab and cilgavimab and requires a minimum dosing interval of 4 weeks.
- Shared decision making regarding product administration is the responsibility of the referring/requesting provider. Please review the shared decision making tool to review all warnings and precautions for this product before administration.
- Risk of hypersensitivity, including anaphylaxis
- Precautions with significant bleeding disorders
- Precautions in patients with cardiac risk factors

Evusheld (tixagevimab/cilgavimab) Allocation Process
- Given a limited quantity of available doses, a tiered approach for allocation of tixagevimab/cilgavimab (Evusheld) will be implemented. Those in Tier 1 (Evusheld) will be given priority to receive tixagevimab/cilgavimab (Evusheld). Patients in each tier will be entered into a lottery to randomly select patients who will receive the product. When >80% of Tier 1 patients have been offered treatment, we will move to Tier 2 and follow similar rules to determine Tier 2 patients.

Does the patient meet the Tier 1 criteria? Evusheld (tixagevimab/cilgavimab)?

Please select all of the following Tier 1 Criteria that are true for this patient:
- Involuntary depletion therapy (e.g. alemtuzumab, rituximab, daratumumab, daratumumab, blinatumomab, lenalidomide, thalidomide, bortezomib, proteasome inhibitor-based therapy or received any of these treatments within the past 12 months)
- T-cell depleting therapy (e.g. alemtuzumab, ATG, any chemotherapy regimen for acute lymphoblastic leukemia within the past 12 months)
- Newly diagnosed or recurrent leukemia or lymphoma (any induction regimen or an HMA + vinblastine)
- Multi-organ failure patients who are on active treatment with any triple or quadruple therapy, or any high-risk and/or refractory disease
- Patients with other immune-compromising conditions in tiers 2 (t2) and 3 (t3) may be considered at the time based on availability/supply
- Severe congenital immunodeficiency (Evusheld is labeled for use for patients ≥12 years)

Does the patient meet any of the Tier 1 Criteria listed above (i.e., one or more boxes above were checked)?

Yes
- No

For prioritization purposes, please complete the below for patient to be considered for next tiers

Select the immune-compromising conditions the patient has

Please select which immune-compromising condition(s) the patient has from the list below:

- Involuntary depletion therapy (e.g. alemtuzumab, rituximab, daratumumab, daratumumab, blinatumomab, lenalidomide, thalidomide, bortezomib, proteasome inhibitor-based therapy or received any of these treatments within the past 12 months)
- T-cell depleting therapy (e.g. alemtuzumab, ATG, any chemotherapy regimen for acute lymphoblastic leukemia within the past 12 months)
- Newly diagnosed or recurrent leukemia or lymphoma (any induction regimen or an HMA + vinblastine)
- Multi-organ failure patients who are on active treatment with any triple or quadruple therapy, or any high-risk and/or refractory disease
- Patients with other immune-compromising conditions in tiers 2 (t2) and 3 (t3) may be considered at the time based on availability/supply

Confirm the patient’s COVID-19 vaccination status (you will need to provide the patient’s name)

Please confirm that the patient has completed the full series of the COVID-19 vaccine for immunocompromised patients (i.e. patient has received at least 3 doses within vaccine protocol) or is otherwise not vaccinated (or 2 doses of the J&J vaccine).

- Yes, fully vaccinated
- No, not vaccinated, or incomplete series

Order antibody testing

Order: MABT-050 COVID-19 Spike Antibodies

Patient eligibility will be reviewed

Note:eligibility does not guarantee a dose will be administered right away based on supply availability, the patient’s name will be entered into a conditional selection process. If the patient is selected to receive a dose you will be notified and will be informed of next steps for scheduling.